Not a very big surprise but androgen-deprivation therapy (ADT) substantially increases the risk for cardiovascular and bone-related problems, as well as for diabetes, according to a review of the medical literature published online April 27 in the journal Cancer. At the University of Texas Health Science Center in Houston, Lockwood G. Taylor wrote a review [...]
When your PSA starts to rise after you have received primary treatment you need to be concerned that your prostate cancer has reoccurred. The first indicator of recurrent prostate cancer is a detectable level of prostate-specific antigen (PSA). Research has demonstrated that PSA doubling time is a reliable tool to distinguish which cancers pose a [...]
A letter from Sens. Tim Johnson (D-SD) and Mike Crapo (R-ID) is circulating in the Senate now and will be sent to the Defense Appropriations Subcommittee on Friday, April 24. Contact your Senators today and ask them to sign the Johnson-Crapo Appropriations letter to increase research funding for prostate cancer at the Department of Defense. [...]
At the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, National Cancer Institute (NCI) Director John E. Niederhuber, M.D., announced major details, such as funding more grants, development of a platform for personalized cancer care, and an accelerated cancer genetics program, that will move cancer research forward in this new economic environment. [...]
Our own Alvin Chin, Prostate Cancer Survivor & Advocate, Virginia Prostate Coalition, joins oncologists Howard Scher MD, Donald S. Coffey, PhD, Peter S. Nelson, MD and representatives from research and the Pharma industry for a round table discussion April 23. You can make your voice heard by joining the conference by phone and emailing questions [...]